<!DOCTYPE HTML>
<!--
	Phantom by HTML5 UP
	html5up.net | @ajlkn
	Free for personal and commercial use under the CCA 3.0 license (html5up.net/license)
-->
<html>
	<head>
		<title>DC Johnson - Neurtral Evolution</title>
		<meta charset="utf-8" />
		<meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no" />
		<link rel="stylesheet" href="assets/css/main.css" />
		<noscript><link rel="stylesheet" href="assets/css/noscript.css" /></noscript>
	</head>
	<body class="is-preload">
		<!-- Wrapper -->
			<div id="wrapper">

				<!-- Header -->
					<header id="header">
						<div class="inner">

							<!-- Logo -->
								<a href="index.html" class="logo">
									<span class="symbol"><img src="images/logo.svg" alt="" /></span><span class="title">DC Johnson - Portfolio</span>
								</a>

							<!-- Nav -->
								<nav>
									<ul>
										<li><a href="#menu">Menu</a></li>
									</ul>
								</nav>

						</div>
					</header>

				<!-- Menu -->
					<nav id="menu">
						<h2>Menu</h2>
						<ul>
							<li><a href="index.html">Home</a></li>
							<li><a href="mangement.html">Managerial Experience</a></li>
							<li><a href="data.p1.html">Data management</a></li>
							<li><a href="publications.html">Publications</a></li>
							<li><a href="elements.html">C.Vs</a></li>
						</ul>
					</nav>

				<!-- Main -->
					<div id="main">
						<div class="inner">
							<h1>Neutral Evolution</h1>
							<p><b>Background</b><br>
								An ICR colleague resurrected the evolutionary theory and married to bulk sequencing data, and argued that some tumour are driven by such strong initial driver, that they evolve neutrally. This approach by <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28827410"> Sotteriva et al </a>  has been <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30374075"> critiqued </a> in the literature. The practical problem is influence of copy numbers and the stringency of cut off R<sup>2</sup>. It is likely that R<sup>2</sup> needs to be assessed for each tumour type, rather than a definitive threshold. The usefulness of this method for clinical predication is questionable, as tumour is neutrality is measured during a particular time span, clearly changing the environment could change a tumour neutral tendency. The measuer could be used could be used a means to assess how targetabilty of a drug, whether a drug affects a tumour directly or  via the micro environment. 
							</p>
							<span class="image main"><img src="images/neu.fig1.png" alt="" /></span>
							<p><b>Distribution</b><br>
							It can be seen in the distribution of sub-clonal mutations below 0.6, there are few sub-clonal mutations, the majority are mutations have a low frequency and can be considered passengers. Looking at cumulative mutations over time. We standard pipeline for the time. Including mutations where the were there were more than 10 reads, with at least 3 mutations. And I only considered samples that had 12 private mutation between a frequency of 0.12 and 2.4. I corrected for copy number and generated a R<sup>2</sup> score.
							</p>
							<span class="image main"><img src="images/neu.fig2.png" alt="" /></span>
							<p><b>Subgroups and mutational signatures</b><br>
							As expected, neutral tumour signature was seen to be enriched in Myeloma subgroups, where disease transition has been shown to more rapid from the precursor MGUS disease. The numbers were small but I was able to show that micro-environment enriched mutation were more prevalent in the non neutral samples, indicating that these samples were likely to be more micro-environment sensitive.

								</p>
							<span class="image main"><img src="images/neu.fig3.png" alt="" /></span>
							<p><b>Survival and response</b><br>
								Indeed, when we compared OS and PFS in auto treated patients, where the bulk of the tumour is removed we see little difference.
								Whilst in non-intensively treated patient received IMIDs, where the response to therapy is micro-environment dependent, we do see a difference in outcome. Assessing independent data-sets from MMRF Commpass cancer-register, we see a similar pattern.</p>
							<span class="image main"><img src="images/neu.fig4.png" alt="" /></span>
							<p>◦ Neutral tumor evolution in myeloma is associated with poor prognosis. Johnson DC, Lenive O, Mitchell J, Jackson G, Owen R, Drayson M, Cook G, Jones JR, Pawlyn C, Davies FE, Walker BA, Wardell C, Gregory WM, Cairns D, Morgan GJ, Houlston RS, Kaiser MF. Blood. 2017 Oct 5;130(14):1639-1643. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28827410"> PMID: 28827410. </a> <br><br>
								◦ Identification of neutral tumor evolution across cancer types. Williams MJ, Werner B, Barnes CP, Graham TA, Sottoriva A. Nature Genetics 2016, Mar;48(3):238-244. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26780609"> PMID: 26780609. </a> <br><br>
								◦ Neutral tumor evolution? Tarabichi M, Martincorena I, Gerstung M, Leroi AM, Markowetz F et al. Nature Genetics 2018, Dec;50(12):1630-1633. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30374075"> PMID: 30374075. </a> <br><br>
								◦ Reply to 'Neutral tumor evolution?' Heide T, Zapata L, Williams MJ, Werner B, Caravagna G, Barnes CP. Nature Genetics 2018, Dec;50(12):1633-1637. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30374073"> PMID: 30374073. </a> <br><br></p><p>
						</div>
					</div>

				<!-- Footer -->
					<footer id="footer">
						<div class="inner">
							<section>
								<h2>Get in touch</h2>
								<form method="post" action="#">
									<div class="fields">
										<div class="field half">
											<input type="text" name="name" id="name" placeholder="Name" />
										</div>
										<div class="field half">
											<input type="email" name="email" id="email" placeholder="Email" />
										</div>
										<div class="field">
											<textarea name="message" id="message" placeholder="Message"></textarea>
										</div>
									</div>
									<ul class="actions">
										<li><input type="submit" value="Send" class="primary" /></li>
									</ul>
								</form>
							</section>
							<section>
								<h2>Follow</h2>
								<ul class="icons">
									<li><a href="#" class="icon brands style2 fa-twitter"><span class="label">Twitter</span></a></li>
									<li><a href="#" class="icon brands style2 fa-facebook-f"><span class="label">Facebook</span></a></li>
									<li><a href="#" class="icon brands style2 fa-instagram"><span class="label">Instagram</span></a></li>
									<li><a href="#" class="icon brands style2 fa-dribbble"><span class="label">Dribbble</span></a></li>
									<li><a href="#" class="icon brands style2 fa-github"><span class="label">GitHub</span></a></li>
									<li><a href="#" class="icon brands style2 fa-500px"><span class="label">500px</span></a></li>
									<li><a href="#" class="icon solid style2 fa-phone"><span class="label">Phone</span></a></li>
									<li><a href="#" class="icon solid style2 fa-envelope"><span class="label">Email</span></a></li>
								</ul>
							</section>
							<ul class="copyright">
								<li>&copy; Untitled. All rights reserved</li><li>Design: <a href="http://html5up.net">HTML5 UP</a></li>
							</ul>
						</div>
					</footer>

			</div>

		<!-- Scripts -->
			<script src="assets/js/jquery.min.js"></script>
			<script src="assets/js/browser.min.js"></script>
			<script src="assets/js/breakpoints.min.js"></script>
			<script src="assets/js/util.js"></script>
			<script src="assets/js/main.js"></script>

			<div>Icons made by <a href="https://www.flaticon.com/authors/eucalyp" title="Eucalyp">Eucalyp</a> from <a href="https://www.flaticon.com/"             title="Flaticon">www.flaticon.com</a> is licensed by <a href="http://creativecommons.org/licenses/by/3.0/"             title="Creative Commons BY 3.0" target="_blank">CC 3.0 BY</a></div>
	</body>
</html>